[Clinical observation on treatment of cancerous hydrothorax by aiyishu injection].
OBJECTIVE
To investigate the therapeutic effects of Aiyishu Injection (AYSI) on cancerous hydrothorax, quality of life (QOF), and cellular immune function of patients.


METHODS
Sixty late-stage cancer patients accompanied hydrothorax were randomly divided into the experimental group (EG) and the control group (CG), with thirty patients in each group. After thoracenteses being carried out in all patients for draining off hydropsy, to the patients in EG, AYSI was medicated, 50 ml by intrathoracic and another 50 ml by intravenous injection; while to the patients in CG chemotherapeutic agent or interleukin-2 (IL-2) was given. The same treatment, thoracentesis and medication, was repeated 3 days later. After 4 weeks, the volume of pleural effusion was measured with B-mode ultrasound to evaluate the therapeutic effects of AYSI. QOF, body weight and T-lymphocyte subsets were compared between the two groups before and after treatment.


RESULTS
The clinical efficacy was significantly higher in EG than that in CG (P < 0.01). Besides, QOF was significantly improved (P < 0.05) and levels of CD3+ , CD4+ , CD4+ /CD8+ in peripheral blood increased in EG after treatment, which were significantly different to those in CG (P < 0.01, P < 0.05).


CONCLUSIONS
AYSI has definite therapeutic effects on cancerous hydrothorax, it could improve QOF and cellular immune function in patients with cancer.
Shi
Jian
J
Department of Oncology, the Forth Hospital Affiliated to Hebei Medical University, Shiji-azhuang. shijian6668@126.com
Wei
Su-ju
SJ
Shan
Bao-en
BE
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications / Q000188:drug therapy; D001517:Coleoptera / Q000737:chemistry; D006801:Humans; D006876:Hydrothorax / Q000188:drug therapy* / Q000209:etiology; D007267:Injections; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy*; D008419:Materia Medica / Q000627:therapeutic use*; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology
D000970:Antineoplastic Agents; D008419:Materia Medica